YINDARA-4 relieves visceral hypersensitivity in irritable bowel syndrome rats via regulation of gut microbiota and serotonin levels

Abstract

Objective: The present study aims to evaluate the in vivo efficacy of YINDARA-4 in improving the symptoms of irritable bowel syndrome (IBS) in a rat model and investigate the impact of YINDARA-4 on potential targets of IBS management, such as the serotonin level in intestinal tissues and the structure and composition of the gut microbiota.

Methods: We developed an IBS rat model by combining stress from maternal separation, acetic acid administration, and restraint. We administered YINDARA-4 water extract to the IBS rat model for 10 consecutive days. The fecal water content, visceral sensitivity, gut microbiota, and serotonin levels in the colonic tissue were then analyzed and compared between the control group, IBS model group, and YINDARA-4-treated groups.

Results: Treatment with YINDARA-4 reversed visceral hypersensitivity in a dose-dependent manner in the experimental rat model of IBS. The relief of visceral hypersensitivity upon treatment with YINDARA-4 involved regulation of the gut microbiota structure and composition, and normalization of elevated serotonin levels in the colon. The decrease in colonic serotonin levels with YINDARA-4 treatment might be associated with a reduction in the abundance of Helicobacter and enrichment of Butyricimonas.

Conclusions: Treatment with YINDARA-4 was beneficial against visceral hypersensitivity in a rat model of IBS. The improved symptoms exhibited in IBS rats were associated with favorably altered gut microbiota and normalization of serotonin levels in the colon.

Keywords

5-Hydroxytryptamine / Gut microbiota / Irritable bowel syndrome / Traditional Mongolian medicine / Visceral hypersensitivity / YINDARA-4

References

[[1]] Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol.2012;10(7):712-721.e4.

[[2]] Canavan C, West J, Card T.The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80.

[[3]] Hong SN, Rhee P-L.Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World [J] Gastroenterol. 2014;20(10):2470-2481.

[[4]] Enck P, Aziz Q, Barbara G, et al.Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014.

[[5]] Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology.2017;152(1):111-123.e8.

[[6]] Collins S, Verdu E, Denou E, et al.The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome. Dig Dis. 2009;27(Suppl 1):85-89.

[[7]] Aroniadis OC, Brandt LJ.Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterol Hepatol (N Y). 2014;10(4):230-237.

[[8]] Yang M, Fukui H, Eda H, et al.Involvement of gut microbiota in the association between gastrointestinal motility and 5HT expression/M2 macrophage abundance in the gastrointestinal tract. Mol Med Rep. 2017;16(3):3482-3488.

[[9]] Yano JM, Yu K, Donaldson GP, et al.Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264-276.

[[10]] Faure C, Patey N, Gauthier C, et al.Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 2010;139(1):249-258.

[[11]] Tack J, Camilleri M, Chang L, et al.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745-767.

[[12]] Lewis JH.The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf. 2011;34(7):545-565.

[[13]] Xi J, Zhong HR, Wucharila T, et al.Herbal textual research of common Mongolian medicine “Du Ge Mo Nong”. China Journal of Chinese Materia Medica. 2016;41(22):4267-4273.

[[14]] Shang Z, Wang D, Shang C, et al.Study on the protective effect of cynanchum against the neuronal damage-free radical, break DNA. [J] Zhelimu Animal Husbandry College. 2000;10(4):8-15.

[[15]] Yu WJ, Chang FH, Jie HX, et al.Quality standard of Cynanchum thesioides (Freyn) K. Schum. Central South Pharmacy. 2014;12(9):9180921.

[[16]] Wang X, Han X, Ren C.Wangshilianpu drink plus talcum, baical skullcap root and Yindari-4 decoction treating animal model of warm disease with damp-heat syndrome and its effects on the inflammation factors of IL-1β, IL-6 and TNF-α. World Chinese Med. 2014;9(11):1524-1527.

[[17]] Yuan HQ, Zuo CX.Chemical constituents of Cynanchum thesioides K. Schum. China Journal of Chinese Materia Medica. 1992;17(12):739-741, 763.

[[18]] Jesus JA, Lago JH, Laurenti MD, et al.Antimicrobial activity of oleanolic and ursolic acids: an update. Evid Based Complement Alternat Med. 2015;2015:620472.

[[19]] Duwiejua M, Zeitlin IJ, Waterman PG, et al.Anti-inflammatory activity of Polygonum bistorta, Guaiacum officinale and Hamamelis virginiana in rats. [J] Pharm Pharmacol. 1994;46(4):286-290.

[[20]] Xiong J, Bui VB, Liu XH, et al.Lignans from the stems of Clematis armandii(“Chuan-Mu-Tong”) and their anti-neuroinflammatory activities. J Ethnopharmacol. 2014;153(3):737-743.

[[21]] Chen MH, Chen XJ, Wang M, et al.Ophiopogon japonicus-a phytochemical, ethnomedicinal and pharmacological review. [J] Ethnopharmacol. 2016;181:193-213.

[[22]] Parasuraman S, Raveendran R, Kesavan R.Blood sample collection in small laboratory animals. [J] Pharmacol Pharmacother. 2010;1(2):87-93.

[[23]] Xu GY, Winston JH, Shenoy M, et al.The endogenous hydrogen sulfide producing enzyme cystathionine-beta synthase contributes to visceral hypersensitivity in a rat model of irritable bowel syndrome. Mol Pain. 2009;5:44.

[[24]] Wang HJ, Xu X, Xie RH, et al.Prenatal maternal stress induces visceral hypersensitivity of adult rat offspring through activation of cystathionine-beta-synthase signaling in primary sensory neurons. Mol Pain. 2018;14:1744806918777406.

[[25]] Caporaso JG, Kuczynski J, Stombaugh J, et al.QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335-336.

[[26]] Dixon P.VEGAN, a package of R functions for community ecology. [J] Veg Sci. 2003;14(6):927-930.

[[27]] Farzaei MH, Bahramsoltani R, Abdollahi M, et al.The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22(4):558-574.

[[28]] Yu FY, Huang SG, Zhang HY, et al.Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis. World [J] Gastroenterol. 2016;22(12):3451-3459.

[[29]] Mawe GM, Hoffman JM.Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8):473-486.

[[30]] Luo M, Zhuang X, Tian Z, et al.Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):14.

[[31]] Distrutti E, Monaldi L, Ricci P, et al.Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World [J] Gastroenterol. 2016;22(7):2219-2241.

[[32]] Pinn DM, Aroniadis OC, Brandt LJ.Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am [J] Gastroenterol. 2014;109(11):1831-1832.

[[33]] Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics,synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol.2014;109(10):1547-1561; quiz 1546, 1562.

[[34]] Moraes-Filho JP, Quigley EM.The intestinal microbiota and the role of probiotics in irritable bowel syndrome: a review. Arq Gastroenterol. 2015;52(4):331-338.

[[35]] Pimentel M, Lembo A, Chey WD, et al.Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl [J] Med. 2011;364(1):22-32.

[[36]] Locke CR, Talley NJ III, Nelson DK, et al.Helicobacter pylori and dyspepsia: a population-based study of the organism and host. Am [J] Gastroenterol. 2000;95(8):1906-1913.

[[37]] Su YC, Wang WM, Wang SY, et al.The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. Am [J] Gastroenterol. 2000;95(8):1900-1905.

[[38]] Kountouras J, Gavalas E, Doulberis M, et al.The effect of trimebutine and/or helicobacter pylori eradication on the gastroesophageal reflux disease, irritable bowel syndrome, and functional dyspepsia overlapping disorders. J Neurogastroenterol Motil. 2019;25(3):473-474.

[[39]] Drossman DA, Morris CB, Hu Y, et al.A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology. 2005;128(3):580-589.

[[40]] Shariati A, Fallah F, Pormohammad A, et al.The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. [J] Cell Physiol. 2019;234(6):8550-8569.

[[41]] Yang C, Qu Y, Fujita Y, et al.Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry. 2017;7(12):1294.

[[42]] Pozuelo M, Panda S, Santiago A, et al.Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep. 2015;5:12693.

[[43]] Martin AM, Lumsden AL, Young RL, et al.Regional differences in nutrient-induced secretion of gut serotonin. Physiol Rep. 2017;5(6):e13199.

[[44]] Reigstad CS, Salmonson CE, Rainey JF III, et al.Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015;29(4):1395-1403.